Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin
OwnerBrian Richard MacDonald, Maria Gabriela Beconi +1inventors
InventorsBrian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
Life of this patent
Estimating the term…
Abstract
The present embodiments are directed to methods of using a crystalline form (such as form A, B, or C, or a methylparaben cocrystal form) or an amorphous form of Bitopertin, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
Claims55
A method of treating erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLPP) in a subject comprising administering a pharmaceutical composition comprising a solid form of Bitopertin having the following structure:
(canceled)
4-6. (canceled)
(canceled)
13-16. (canceled)
(canceled)
21-22. (canceled)
24-27. (canceled)
29-31. (canceled)
(canceled)
35-36. (canceled)
38-43. (canceled)
45-49. (canceled)
51-55. (canceled)
57-60. (canceled)
62-68. (canceled)
70-88. (canceled)
94-96. (canceled)
99-101. (canceled)
104-106. (canceled)
(canceled)
111-113. (canceled)
(canceled)
Dependencies are inferred from the claim text.